Across five human cohorts, the gut bacterium Roseburia hominis was depleted in metabolic disorders and rose after dietary interventions. Strain-level variation in its oleate hydratase gene, ohyA, tracked cardiometabolic severity. The enzyme converts oleic acid to 10-hydroxystearic acid (10-HSA); a variant carrying five missense substitutions lost most activity. In high-fat-diet mice, 10-HSA reduced weight gain, improved insulin sensitivity, and lessened hepatic steatosis, apparently by activating PPAR-linked liver lipid pathways rather than reshaping the microbiota.
The cohort-to-mechanism pipeline here is unusually complete, moving from human association to enzyme chemistry to a rescue experiment, which strengthens the biological plausibility of a diet-responsive microbial axis. Still, the causal evidence comes entirely from mice on a high-fat diet; the human data are associational, and the mediation analysis only shows statistical overlap, not proof that 10-HSA drives human outcomes. Whether 10-HSA reaches liver-relevant concentrations in people, and at what dose, is unknown. Adults should not read this as a case for buying Roseburia probiotics or 10-HSA supplements, neither of which has human trial support. The practical takeaway remains conventional: the dietary patterns that raise R. hominis, typically fiber-rich, plant-forward eating, are already linked to better metabolic health. This work is a preprint and has not been peer reviewed, so effect sizes and conclusions may shift. It is best viewed as an incremental advance that nominates a specific microbial enzyme as a future therapeutic or stratification target rather than a change in clinical practice.